The annual ASCO (American Society of Clinical Oncology) is recognized as the world's most important oncology conference. With more and more biopharmaceutical companies entering the field of oncology in recent years, ASCO has attracted more attention. The summary night will also help determine which companies will stand out this year, and John Patroll, an analyst at Endpts, a foreign medical website, conducted an inventory of the winners and losers at the ASCO event based on the summary released by ASCO.
Big winner Loxo Oncology
Loxo Oncology is the biggest winner of ASCO's summary night, and its share price soared 18% overnight as its investors found Loxo Oncology's RET inhibitor LOXO-292 in 32 evaluable RET-positive late entities The overall response rate in patients with tumors reached 69%, of which: the total remission rate of non-small cell lung cancer (NSCLC) was 65%, and the total remission rate of papillary thyroid cancer was 83%. In addition, as many as 84% ​​(27/32) of patients have tumor size reductions of 19%-67%.
However, the above data has brought disadvantages to Loxo Oncology's competitors. Blueprint's RET inhibitor BLU-667 has been favored by investors before. The investors compared the efficacy data of LOXO-292 and BLU-667 and found that The efficacy of LOXO-292 was better, which directly led Blueprint to fall 8% in pre-market trading on Thursday.
In addition, Loxo CEO Josh Bilenker said that the summary data released this time is only as of January 5, the company will also release data as of April at the ASCO meeting, which is better than the summary data, Josh Bilenker also stressed LOXO-292 has been selected as the best project of ASCO, which makes Loxo become the focus of the industry.
Novartis Kymriah VS Gilead Yescarta
As two companies that have received significant FDA approvals in the CAR-T field, the contest between Novartis's Kymriah and Gilead's Yescarta has been fierce.
Recently, a team from Beijing directly compared two therapies for the treatment of CD19-positive B-cell acute lymphoblastic leukemia, and found that Kymriah seems to have a unique advantage. Specific treatment data: the total response rate was 100% in the Kymriah treatment group and 89% in the Yescarta treatment group. In addition, all 5 patients in the Yescarta treatment group developed severe grade 3 or 4 cytokine release syndrome.
However, Evercore ISI analyst Umer Raffat said the findings were very provocative, but further details are needed.
Big loser Jounce
Contrary to the above Loxo Oncology, Jounce became the big loser of ASCO's summary night, because the latest data on its immunotherapeutic drug JTX-2011 showed that after 7 patients with gastric cancer received JTX-2011 monotherapy, only 1 patient Relief was achieved. At the same time, JTX-2011 achieved only 2 of the 19 patients treated with Bristol-Myriad's tumor immunotherapy Opdivo (11%), and the performance was not ideal in triple-negative breast cancer. .
Although Jounce stressed that the patients in this study were patients who had been over-pretreated before, the company's stocks inevitably saw a 26% plunge. In addition, Celgene also had a Jounce. The company was involved in the JTX-2011 cooperation and was involved.
Nektar's NKTR-214 showed a small shock
Nektar participated in the ASCO with its research drug NKTR-214, a CD122 agonist that stimulates cancer cells by targeting CD122-specific receptors on the surface of immune cells. And increase PD-1 expression on these immune cells. Earlier this year, Nektar and Bristol-Myers Squibb (BMS) conducted a global strategic development and commercialization of their NKTR-214 drug, which was worth $3.6 billion.
Previously, many of NKTR-214's data were excellent, such as a total rate of 63% in the first-line treatment of advanced melanoma. However, in the latest published data, the rate of NKTR-214 treatment for melanoma decreased to 52%. In addition, renal cell carcinoma remission rate also dropped from 71% in the Q4 report to 54%. Overall, the overall response rate tends to decline over time. However, these data cannot all negate the NKTR-214. Investors are still confident and expecting the prospects of the NKTR-214.
Merck Cancer Pipeline's multiple products perform brilliantly
In this ASCO abstract, Merck has published the latest data on several products in the cancer drug pipeline, such as the c-Met receptor tyrosine kinase inhibitor tepotinib for the treatment of 15 advanced non-small cells carrying the MET14 exon skip mutation. Data from lung cancer patients showed a 60% partial response, and analysts believe that sales of the drug will reach $650 million by 2030.
In combination therapy, Merck introduced the M7842 drug, a TGF-β trap/anti-PD-L1 bifunctional immunotherapy fusion protein with a total response rate of 71.4 in patients with high PD-L1 expression. %.
At the same time, Merck's other heavy drug, Bavencio, also achieved good results in the initial combination treatment. In a study called JAVELIN Lung 101, Bavencio was combined with the Pfizer ALK inhibitor lolatinib for ALK-positive patients. The objective response rate reached 46.4% (12 partial remissions and 1 complete remission).
Kelp is rich in nutritions and multipl minerals.It make people full but diets. It is the most favorite choice of people with hypertension, hyperlipemia, hyperglycemia.
Extract from the natural plant of Laminaria Japonica which is light grey powder after the special extract processing.They are powder form with good color. It's mainly used for Medicine, cosmetic, food additive field as raw materials.It's very good for human health.
Kelp has anti-can-cer and anti-virus properties related to its antioxidant content and its ability to stimulate your immune system
Kelp Alginate Oligosaccharide,Alginate Oligosaccharide,Seaweed Extract,Kelp Extract For Plants
Shandong Haizhibao Ocean Science and Technology Co.,Ltd. , https://www.haizhibaoseafood.com